Make us your home page

Estrogen linkedto benign lumps

WASHINGTON — Add another risk to hormone therapy after menopause: benign breast lumps.

One type of hormone therapy — estrogen plus progestin — already is known to increase the risk of breast cancer. But a major study of women able to use estrogen alone didn't find that link.

Researchers reported a new wrinkle Tuesday: Those estrogen-only users doubled their chances of getting noncancerous breast lumps. That's a concern not only because of the extra biopsies and worry those lumps cause, but because a particular type — called benign proliferative breast disease — is suspected of being a first step toward developing cancer 10 years or so later.

About one in five women undergo a breast biopsy within a decade of starting annual mammograms, and most abnormalities turn out to be benign.

The latest work, published in the Journal of the National Cancer Institute, re-examines data from the landmark Women's Health Initiative. Only women who have undergone hysterectomies are able to use estrogen-only therapy, and the WHI originally included more than 10,000 of those women, who were given either estrogen or a placebo and tracked for about seven years.

A team led by Dr. Tom Rohan of the Albert Einstein College of Medicine in New York identified 232 cases of benign proliferative breast disease. The estrogen group had twice the risk of developing the abnormality compared with the placebo group.

Health roundup

Six-way kidney swap: Johns Hopkins surgeons in Baltimore transplanted a half-dozen kidneys simultaneously, an operation believed to be the first of its kind, hospital officials announced Tuesday. The transplants conducted Saturday were made possible when a donor was matched with one of six transplant candidates. Five of the candidates had a willing donor whose kidney was incompatible with their particular friend or relative, but a match for another of the six.

More heparin concerns: The scope of concerns about the possible ill effects of a contaminated blood thinner from China grew significantly Tuesday as federal regulators urged makers of many kinds of medical devices that contain the drug heparin to test their supplies. The products to be tested cover a spectrum of equipment and uses and include kits that flush out IV lines, stents and certain diagnostic tests. A Food and Drug Administration spokeswoman said it was "largely a precautionary move."

Times wires

Estrogen linkedto benign lumps 04/08/08 [Last modified: Tuesday, April 8, 2008 11:55pm]
Photo reprints | Article reprints


Join the discussion: Click to view comments, add yours